

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.

Tel.: (91-22) 4324 4324

Fax: (91-22) 4324 4343

Website: www.sunpharma.com

Email: secretarial@sunpharma.com

CIN: L24230GJ1993PLC019050



October 07, 2024

National Stock Exchange of India Limited
Scrip Symbol: SUNPHARMA

BSE Limited
Scrip Code: 524715

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Regulatory Order

This is to inform that the Company has received orders passed by statutory authority. Relevant details, as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, are provided in Annexure A.

The Company shall take appropriate action in the matter.

For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)

Company Secretary and Compliance Officer

ICSI Membership No.: A23983

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.

Tel.: (91-22) 4324 4324

Fax: (91-22) 4324 4343

Website: www.sunpharma.com

Email: secretarial@sunpharma.com

CIN: L24230GJ1993PLC019050



Annexure A

Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Sl. No.	Particulars	Information
a)	Name of the authority	Office of the Asstt. Commissioner of Customs, ICD, Dhannad (OIO No. 05/Drawback/ AC/ ICD -Dhannad/2024-25
b)	Nature and details of the action(s) taken, initiated, or order(s) passed	Order passed u/s 75 and 117 of the Customs Act, 1962, imposing penalty Rs. 1,00,000/-
c)	Date of receipt of direction or order, including any ad-interim or interim orders or any other communication from the authority	October 07, 2024
d)	Details of the violation(s)/ contravention(s) Committed or alleged to be committed	Re-Classification of HSN.
e)	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	There is no material impact on the Company's financial, operation or other activities.